# AdBio partners

> AdBio partners is a VC fund in Paris backing Biotechnology and Health Care. See 32 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 32
- Last investment: Feb 2026
- Lead investor: 41%
- Fund size: $116M
- Last fund: Sep 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/adbiopartners/
- Website: https://adbio.partners/

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

## Contacts

5 contacts available for AdBio partners. Shizune tracks 6 team members at AdBio partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/advent-france-biotechnology?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.2M–$18M |
| Series A | $18M–$37M |
| Venture - Series Unknown | $2.2M–$16M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 17 | 53% |
| Health Care | 6 | 19% |
| Pharmaceutical | 4 | 13% |
| Medical | 3 | 9% |
| Biopharma | 2 | 6% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 14 | 44% |
| Series A | 4 | 13% |
| Venture - Series Unknown | 3 | 9% |
| Series B | 2 | 6% |
| Funding Round | 2 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 11 | 34% |
| Spain | 3 | 9% |
| Belgium | 3 | 9% |
| Denmark | 1 | 3% |
| Switzerland | 1 | 3% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alain Huriez | President & General Partner | 8 | https://shizune.co/investors/profile/alain-huriez |
| Arnaud Foussat | Operating Partner | 0 | https://shizune.co/investors/profile/arnaud-foussat-dfd6 |
| Matthieu Coutet | Managing Partner | 8 | https://shizune.co/investors/profile/matthieu-coutet |
| Francesc Dosrius | Junior Analyst | 0 | https://shizune.co/investors/profile/francesc-dosrius |
| Jeremie Mariau | Operating Partner | 0 | https://shizune.co/investors/profile/jeremie-mariau |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Orikine Bio | Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders. | $3.2M | Seed | Feb 02, 2026 |  |
| ARTHEx Biotech | ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M | Series B | Sep 17, 2025 |  |
| Integra Therapeutics | Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $3.2M | Seed | Sep 17, 2025 |  |
| Integra Therapeutics | Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $12.6M | Seed | Sep 08, 2025 |  |
| EvlaBio | EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical). | $24.6M | Seed | Jul 07, 2025 |  |
| Cephagenix | Cephagenix focuses on identifying and developing new, effective migraine therapies. | $9.3M | Seed | Jan 16, 2025 |  |
| Tenpoint Therapeutics | Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics. |  | Venture - Series Unknown | Dec 11, 2024 |  |
| Augustine Therapeutics | Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $18.2M | Series A | Jun 26, 2024 |  |
| AgomAb Therapeutics | AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $100.8M | Series C | Oct 11, 2023 |  |
| Orikine Bio | Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders. | $6.2M | Seed | Jul 18, 2023 |  |

10 of 32 investments shown.

## Co-investors
- [Invivo Capital Partners](https://shizune.co/investors/profile/invivo-capital-partners) — VC Fund, 8 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 5 deals together
- [Asabys Partners](https://shizune.co/investors/profile/asabys-partners) — VC Fund, 4 deals together
- [CDTI Innovación's INNVIERTE program](https://shizune.co/investors/profile/cdti-innovaci%C3%B3n-s-innvierte-program) — VC Fund, 4 deals together
- [Columbus Venture Partners](https://shizune.co/investors/profile/columbus-venture-partners) — VC Fund, 4 deals together
- [V-Bio Ventures](https://shizune.co/investors/profile/v-bio-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Europe](https://shizune.co/investors/biotechnology-investors-europe)
- [Biotechnology VC Funds in Europe](https://shizune.co/investors/biotechnology-vc-funds-europe)
- [Biotech Investors in Europe](https://shizune.co/investors/biotech-investors-europe)
- [Biotech VC Funds in Europe](https://shizune.co/investors/biotech-vc-funds-europe)
- [Biotechnology Investors in France](https://shizune.co/investors/biotechnology-investors-france)
- [Biotechnology VC Funds in France](https://shizune.co/investors/biotechnology-vc-funds-france)

## FAQ

### What does AdBio partners invest in?

AdBio partners invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 32 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is AdBio partners's check size?

AdBio partners typically joins rounds of $2.2M–$18M at Seed, $18M–$37M at Series A and $2.2M–$16M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds AdBio partners participates in.

### How do I contact AdBio partners?

Public channels for AdBio partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at AdBio partners?

The team at AdBio partners includes Alain Huriez (President & General Partner), Arnaud Foussat (Operating Partner) and Matthieu Coutet (Managing Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co